Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703) 308-6564

Slides:



Advertisements
Similar presentations
Patenting Antisense Oligonucleotides and Methods
Advertisements

Enablement Issues in the Examination of Antibodies
Examining Pharmaceutical Claims of Immense Scope Gary L. Kunz Supervisory Patent Examiner Art Unit Michael Woodward Training Quality.
Written Description: Antibodies Bennett Celsa TC 1600 QAS
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
1 Types of Vaccines and Patentability Considerations Christina Chan Supervisory Primary Examiner Art Unit 1644 Phone:
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
Common Claim Breadth Issues in Plant- Related Applications Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
Enablement of Method Claims Encompassing the Immunotherapy of Cancer Gary B. Nickol, Ph.D. Supervisory Patent Examiner Art Unit: 1646 United States Patent.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
Gene Therapy: Overcoming Enablement Rejections Karen M. Hauda Supervisory Patent Examiner Art Unit 1632 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Antibody Patents in the United States Dan Altman Knobbe Martens Olsen & Bear, LLP Dan Altman Knobbe Martens Olsen & Bear, LLP.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Animals and Transgenesis Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic.
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Assessing Compliance with the Utility Requirement of 35 U.S.C. § 101 based on the Sequence Homology Dave Nguyen, tQAS TC
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Microarrays: Tools for Proteomics
Bacterial Physiology (Micr430)
Issues in Patenting Proteins Jon P Weber, SPE 1657.
CISC667, F05, Lec24, Liao1 CISC 667 Intro to Bioinformatics (Fall 2005) DNA Microarray, 2d gel, MSMS, yeast 2-hybrid.
A comparative analysis with a harmonizing perspective A RT. 123(2) EPC AND US W RITTEN D ESCRIPTION 1 © AIPLA 2015 Enrica Bruno - Steinfl & Bruno LLP.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
Proteomics Understanding Proteins in the Postgenomic Era.
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
1 Intellectual Property Protection for Plants in the United States Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Patenting Antibodies in Europe
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
March 2009 Current Status of Biotech Patenting In India Kausalya Santhanam Ph.D Patent Agent USPTO, IPO Confidential.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Patenting Interfering RNA
Patenting Biotechnology in Japan and recent hot issues AIPLA Mid-Winter Meeting January 25, 2012 Ayako Kobayashi TMI Associates.
Intellectual Property, Patents & Technology Transfer Sagar Manoli Shashidhar, Philippe Abdel-Sayed Responsible Conduct in Biomedical Research EPFL,
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
Finish up array applications Move on to proteomics Protein microarrays.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
[ w w w. d u a n e m o r r i s. c o m ] ● ©2008 Duane Morris LLP. All Rights Reserved. Duane Morris is a registered service mark of Duane Morris LLP. ●
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
“The Squeeze” Art and Enablement Together Yvonne L. Eyler, SPE AU 1646.
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
Gene Sleuthing Lorraine Sartori Majid Masso Paul R. McCreary.
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
A density gradient is formed in a centrifuge tube, and a mixture of proteins in solution is placed on top of the gradient. To identify the estradiol receptor,
Ch Epidemiology Microbiology.
Patenting Biotechnology in Japan and recent hot issues
Patentability Issues and Mechanism Claims
Management of advanced renal cancer
Stem Cells Peter Paras, Jr.
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)

What is Proteomics? Proteomics refers to the systematic analysis of protein profiles of entire cells, tissues, organisms, or species. It represents the protein counterpart to the analysis of gene function.

Why is Proteomics Important? Identification of proteins in normal and disease conditions –Investigating epidemiology and taxonomy of pathogens –Analysis of drug resistance Identification of pathogenic mechanisms –Reveals gene regulation events involved in disease progression Pin-point targets for drug discovery Contributes to understanding of gene function

Proteomic Methodologies Analysis of protein expression patterns Analysis of protein Sequence Information Analysis of protein structure/function relationships

What is an “orphan” receptor? An “orphan” receptor is a receptor with no known biological function. An “orphan” receptor is a receptor with no known ligand.

Patentability Patent Statutes –35 USC 101, Utility –35 USC 102, Anticipation –35 USC 103, Obviousness –35 USC 112, 1st Paragraph, enablement –35 USC 112, 1st Paragraph, written description –35 USC 112, 2nd Paragraph

Expression Patterns 2D Gel

Specification The specification discloses 2D gels of proteins present in prostate cancer cell lysates and normal cell lysates. A polypeptide located in a spot unique to prostate cancer cells was isolated and sequenced (SEQ ID NO: 1) SEQ ID NO: 1 has 45% homology to WOW, a G protein coupled receptor which is up-regulated in prostate cancer which binds ligand B. Blocking of WOW/ligand B binding inhibits prostate cancer growth.

An Example Claim An isolated polypeptide comprising SEQ ID NO: 1.

Utility Consideration The asserted utility for SEQ ID NO: 1 is for use in screening assays to identify agents which bind to it. The agents are then to be used to inhibit prostate cancer growth. The asserted utility is based on the 45% homology to WOW receptor.

Sequence Homology is Usually Insufficient to Establish Utility Receptor function cannot be reliably predicted from DNA or protein sequence homology Evolutionarily-related protein families may have both overlapping and distinct features

Example #1 of Homology being Insufficient Criteria for Utility Transforming Growth Factor (TGF- beta) Family –OP-1 induces metanephrogenesis whereas closest related TGF-beta family members—BMP-2 and TGF-beta1— have no effect on metanephrogenesis under identical conditions

Example #2 of Homology Being Insufficient Criteria for Utility Platelet-derived Growth Factor (PDGF) Family –VEGF, a member of the PDGF family, is mitogenic for vascular endothelial cells but not for vascular smooth muscle cells –PDGF is mitogenic for vascular smooth muscle cells but not for vascular endothelial cells

Example #3 of Homology Being Insufficient Criteria for Utility Vertebrate growth hormone of 198 amino acids becomes an antagonist (inhibitor of growth) when a single amino acid is changed. Even 99% homology does not allow predictability in this instance.

Utility Considerations for the Claim Example SEQ ID NO: 1 is an “orphan” receptor with no known ligand and no known function. The asserted utility is based solely on sequence homology to a G protein coupled receptor. G protein coupled receptors are a large and diverse family of receptors with diverse functions and properties, having no well established utility based on family membership.

Conclusion The claimed polypeptide would not be found to have a specific, substantial, and credible asserted or well established utility.

Specification # 2 The specification still discloses 2D gels of prostate cancer and normal cell lysates. The polypeptide of SEQ ID NO: 1 is an “orphan” receptor. Antibodies were generated to SEQ ID NO: 1 The antibodies were used in a series of binding assays to demonstrate a clear correlation between presence of high levels of SEQ ID NO: 1 and prostate cancer.

An Example Claim An isolated polypeptide comprising SEQ ID NO: 1.

Utility Consideration The asserted utility for SEQ ID NO: 1 is for use to diagnose prostate cancer.

Utility Conclusion The asserted utility is specific to the polypeptide of SEQ ID NO: 1. The asserted utility is substantial. The asserted utility is credible.

Written Description Considerations

An Example Claim Set An isolated polypeptide comprising at least 10 contiguous amino acids of SEQ ID NO: 1. An isolated polypeptide having at least 45% identity to the polypeptide of SEQ ID NO: 1.

Satisfying Written Description –Weigh factual considerations in view of level of skill and knowledge in the art Complete or partial structure Physical and/or chemical properties Functional characteristics Correlation between structure and function Method of making Combinations of the above

Written Description Analysis Physical properties of a single polypeptide are disclosed, ie molecular weight and pI by 2D gel electrophoresis and its sequence. The physical properties of polypeptides comprising 10 amino acids or of polypeptides having 45% identity to SEQ ID NO: 1 are not disclosed or known in the art. No biological function of the polypeptide of SEQ ID NO: 1 is disclosed. The isolated polypeptide is an “orphan” receptor. No structural to functional correlation is disclosed between core structural features needed to retain function in the two claimed genus of polypeptides.

Conclusion Applicant was not in possession of the claimed genus of isolated polypeptides.

Enablement Considerations

Satisfying the Enablement Requirement Factors to be considered, In re Wands, 858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)Factors to be considered, In re Wands, 858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988) Quantity of experimentation necessary Amount of direction or guidance presented Presence or absence of working examples Nature of the invention State of the prior art Relative skill of those in the art Predictability or unpredictability of the art Breadth of the claims

Enablement Analysis No guidance regarding the critical structural features of the polypeptide of SEQ ID NO: 1. –Which 10 amino acids are essential to functional and physical properties? –Where over the length of the polypeptide may changes be made up to 45% identity and still retain functional and physical properties? There is no function for the isolated polypeptide. It is an “orphan” receptor. It is not predictable that the scope of the claimed polypeptides could be used to diagnose prostate cancer.

Conclusion The specification was not enabling for the scope the claimed isolated polypeptides.

Solution Claim: An isolated polypeptide comprising SEQ ID NO: 1.

Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)